查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1808386

In Silico臨床試驗市場按產品類型、階段、技術平台、應用、治療領域和最終用戶分類－2025-2030 年全球預測

In Silico Clinical Trials Market by Product Type, Phase, Technology Platform, Application, Therapeutic Area, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計In Silico臨床試驗市場規模將在 2024 年達到 35 億美元，2025 年達到 38.1 億美元，2030 年達到 59.7 億美元，複合年成長率為 9.27%。

主要市場統計數據
基準年2024年 35億美元
預計2025年 38.1億美元
預測年份 2030 59.7億美元
複合年成長率（%） 9.27%

In Silico臨床試驗的出現及其改變全球藥物開發平臺的潛力

In Silico藥物研發的革新至關重要，它利用強大的運算能力和先進的建模技術來模擬人體生理機能。透過整合機械模型、數位雙胞胎框架和虛擬患者隊列，研究人員能夠以前所未有的速度和深度探索治療方案。這種方法減少了對傳統人體試驗的依賴，並透過在物理測試開始前識別潛在風險來增強早期安全性分析。因此，製藥團隊能夠靈活地迭代給藥方案並完善通訊協定，而不會讓志願者面臨可避免的傷害。

先進的模擬和建模技術將識別重新定義臨床試驗方法的變革範式

隨著相關人員擴大採用模擬主導的方法，臨床試驗範式正在發生翻天覆地的變化。曾經僅依賴體內試驗的傳統範式正在被能夠捕捉患者個體差異和機制細微差別的整合式數位解決方案所取代。近年來，人工智慧和機器學習演算法已將自適應學習引入研究設計軟體，從而實現即時方案調整，並降低代價高昂的後期失敗的可能性。

研究 2025 年美國新關稅對In Silico臨床試驗創新的經濟與管理影響

自2025年起，針對進口軟體組件和專用計算硬體的新關稅將開始影響美國In Silico臨床試驗的經濟狀況。雖然這些措施旨在促進國內製造業發展並確保關鍵供應鏈安全，但也為依賴高效能伺服器、圖形處理單元和第三方演算法庫的臨床試驗贊助者帶來了額外成本。因此，一些公司正在與供應商進行策略性談判，以緩解價格波動並確保其模擬工作流程的連續性。

揭示核心細分洞察，揭示不同產品類型、階段和技術平台的市場動態

仔細研究市場細分，可以深入了解電腦模擬臨床試驗生態系統中各個方面如何相互作用並推動其應用。按產品類型細分，可以發現諮詢與培訓、客製化模擬服務以及模型開發與檢驗等服務產品與包含模擬平台、臨床試驗設計工具和虛擬患者建模應用程式的軟體解決方案之間互補的作用。這些類別結合，為尋求專業知識和技術基礎的研究團隊提供端到端的支援。

解讀塑造全球In Silico臨床試驗格局的區域與策略差異

分析In Silico臨床試驗的地理特徵，可以揭示影響其採用和發展軌蹟的地區特定促進因素和障礙。在美洲，對生命科學基礎設施的強勁投資，以及包括頂尖學術機構和委外研發機構在內的協作生態系統，加速了先進模擬框架的採用。北美監管的清晰度，尤其是《模型導向藥物開發指南》，進一步鼓勵了小型創新和成熟製藥公司的早期採用。

重點介紹推動In Silico測試解決方案創新和競爭優勢的關鍵組織及其策略性舉措

在In Silico臨床試驗的競爭格局中，領先的公司已經規劃出清晰的創新路徑，彰顯了該領域的活力。一些先鋒公司已投入大量資金打造專有模擬平台，這些平台整合了動態和數據驅動方法，為虛擬患者建模和試驗設計提供承包解決方案。其他公司則建立了專業服務部門，提供客製化模擬程序和檢驗服務，使申辦方能夠將複雜的建模工作外包，同時保持嚴格的品管。

為產業領導者建議策略行動，以加速採用模擬臨床試驗環境並最佳化結果

為了充分發揮In Silico臨床試驗的價值，產業領導者必須採取多管齊下的方法，平衡策略投資、跨學科協作和監管參與。首先，建立專門的管治框架，確保建模標準、驗證通訊協定和資料管理實務符合內部品質基準和監管要求。促進透明的模型開發和文件工作流程，使組織能夠簡化監管提交流程，並與監督機構建立信任。

了解支持In Silico臨床試驗市場分析的深度、可靠性和可重複性的嚴格調查方法

此項分析的基礎是一套全面的調查方法，旨在確保研究的深度、嚴謹性和可重複性。研究流程始於對同行評審文獻和監管指南文件的系統性回顧，旨在建立基礎定義並確定In Silico模擬的最佳實踐。這些見解被納入一系列結構化的專家訪談中，訪談對象包括臨床科學家、計算生物學家、監管專家和技術提供商，旨在獲取關於新興趨勢、驗證挑戰和應用障礙的第一手觀點。

綜合關鍵要點和未來觀點，為相關人員提供In Silico臨床試驗策略軌蹟的資訊

隨著計算建模技術的不斷成熟，In Silico臨床試驗有望重新定義藥物開發和監管批准的框架。動態框架、數位雙胞胎結構和高級分析技術的整合已被證明能夠最佳化研究設計、增強安全性分析並縮短上市時間。此外，模擬結果與實證結果之間的日益一致性凸顯了該方法的可靠性，並正在推動其在申辦者、監管機構和臨床研究人員中的廣泛認可。

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章市場動態

  • 開發混合電腦模擬和真實世界證據平台，以加速腫瘤藥物的核准流程
  • 在全球主要市場實施法規結構
  • 整合機械數位雙胞胎技術用於兒科罕見疾病藥物研發
  • 採用先進的人工智慧驅動的藥物動力學和動態模型，為個人化虛擬患者群體提供指導
  • 利用雲端基礎的高效能運算將虛擬臨床試驗擴展到不同地區的人群

第6章 市場洞察

  • 波特五力分析
  • PESTEL分析

第7章 2025年美國關稅的累積影響

第8章In Silico臨床試驗市場（依產品類型）

  • 服務
    • 諮詢和培訓
    • 客製化模擬服務
    • 模型開發與檢驗
  • 軟體解決方案
    • 模擬軟體
    • 測試設計軟體
    • 虛擬病人建模

第9章In Silico臨床試驗市場（依階段）

  • 第一階段
  • 第二階段
  • 第三階段
  • 第四階段

第 10 章In Silico臨床試驗市場技術平台

  • 人工智慧和機器學習
  • 雲端基礎的仿真
  • 數位雙胞胎
  • 機制建模
  • 虛擬患者群體

第 11 章。In Silico臨床試驗市場（按應用）

  • 疾病模型
  • 藥物開發
  • 醫療設備測試

第 12 章In Silico臨床試驗市場（按治療領域）

  • 心血管系統
    • 心律不整模擬
    • 動脈硬化模擬
    • 心臟衰竭模型
  • 感染疾病
    • 寄生蟲病預測
    • 病毒感染模擬
  • 神經病學
    • 阿茲海默症模擬
    • 癲癇模擬
    • 帕金森氏症模型
  • 腫瘤學
    • 造血系統惡性腫瘤
    • 固態腫瘤
  • 罕見疾病
    • 遺傳疾病模擬
    • 孤兒藥建模

第 13 章。In Silico臨床試驗市場（按最終用戶）

  • 學術研究機構
  • 合約研究組織
  • 醫療設備公司
  • 製藥和生物技術公司
  • 監管機構

14.美洲In Silico臨床試驗市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

15. 歐洲、中東和非洲In Silico臨床試驗市場

  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 阿拉伯聯合大公國
  • 沙烏地阿拉伯
  • 南非
  • 丹麥
  • 荷蘭
  • 卡達
  • 芬蘭
  • 瑞典
  • 奈及利亞
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波蘭
  • 瑞士

16. 亞太地區In Silico臨床試驗市場

  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • 印尼
  • 泰國
  • 菲律賓
  • 馬來西亞
  • 新加坡
  • 越南
  • 台灣

第17章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Abzena Ltd.
    • Aitia NV
    • Certara, Inc.
    • Dassault Systemes SE
    • Evotec SE
    • Exscientia Limited
    • GNS Healthcare Inc.
    • IBM Corporation
    • ICON plc
    • Immunetrics Inc.
    • Insilico Medicine, Inc.
    • InSilicoTrials Technologies SpA
    • IQVIA Holdings Inc.
    • Novadiscovery SA
    • PAREXEL INTERNATIONAL, INC.
    • Recursion Pharmaceuticals, Inc.
    • Schrodinger, Inc.
    • Simulations Plus, Inc.
    • The AnyLogic Company
    • Virtonomy GmbH
    • WuXi AppTec Co., Ltd.
    • ZMT Zurich MedTech AG

第18章 研究人工智慧

第19章 研究統計

第20章 研究聯絡人

第21章 研究報導

第22章 附錄

Product Code: MRR-742BD517F92A

The In Silico Clinical Trials Market was valued at USD 3.50 billion in 2024 and is projected to grow to USD 3.81 billion in 2025, with a CAGR of 9.27%, reaching USD 5.97 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 3.50 billion
Estimated Year [2025] USD 3.81 billion
Forecast Year [2030] USD 5.97 billion
CAGR (%) 9.27%

Charting the Emergence of In Silico Clinical Trials and Their Potential to Revolutionize Drug Development Pipelines Worldwide

Marking a pivotal moment in the evolution of drug development, in silico clinical trials harness computational power and sophisticated modeling to simulate human physiology. By integrating mechanistic modeling, digital twin frameworks, and virtual patient cohorts, researchers explore therapeutic scenarios with unprecedented speed and depth. This approach reduces reliance on traditional human trials and enhances safety profiling at early stages by identifying potential risks before physical testing begins. Consequently, pharmaceutical teams gain the agility to iterate on dosing regimens and refine protocols without exposing volunteers to avoidable hazards.

Furthermore, regulatory bodies have shown growing receptivity to model-informed applications, ushering in collaborative dialogues that emphasize validation and reproducibility. As the scientific community collectively grapples with rising R&D costs and shifting ethical standards, in silico methodologies provide a scalable alternative that aligns with both cost containment and patient welfare objectives. Consequently, organizations that adopt these advanced simulations position themselves at the vanguard of innovation, leveraging holistic insights that marry biological plausibility with statistical rigor.

Moreover, interdisciplinary collaborations between computational scientists, clinicians, and data engineers foster the development of robust frameworks capable of modeling diverse therapeutic areas. Transitioning from proof-of-concept studies to scalable platforms, stakeholders can streamline trial design and reduce cycle times. Ultimately, this convergence of expertise underscores the transformative potential of in silico trials to redefine the paradigm of evidence generation in modern drug development.

Identifying the Transformative Paradigms That Are Redefining Clinical Trial Methodologies Through Advanced Simulation and Modeling Technologies

Clinical trial paradigms have undergone a seismic transformation as stakeholders increasingly embrace simulation-driven methodologies. Traditional frameworks that once relied exclusively on in vivo testing are giving way to integrative digital solutions capable of capturing patient variability and mechanistic nuances. In recent years, artificial intelligence and machine learning algorithms have infused trial design software with adaptive learning, empowering protocol adjustments in real time and reducing the likelihood of costly late-stage failures.

Beyond algorithmic advancements, cloud-based architectures now enable secure, scalable computing resources that democratize access to complex simulations. This shift not only accelerates cross-organizational collaboration but also ensures compliance with evolving regulatory standards through traceable data lineage and automated validation workflows. Meanwhile, digital twin constructs reify individual patient profiles, allowing researchers to simulate responses across virtual cohorts that reflect demographic diversity and comorbidity patterns more accurately than ever before.

In parallel, the maturation of mechanistic modeling has fostered greater confidence among clinical stakeholders, as in silico predictions begin to align with empirical outcomes observed in physical trials. Such convergence has precipitated a broader cultural acceptance, with research teams adopting hybrid trial designs that blend simulated arms with traditional cohorts. As a result, sponsors and investigators can navigate protocol feasibility, refine endpoint selection, and optimize resource allocation with enhanced precision.

Regulatory harmonization initiatives across major markets have further catalyzed this transformation, establishing guidelines that delineate acceptable model validation criteria and risk-based assessment approaches. Consequently, stakeholders can pursue innovative trial designs with greater clarity on evidentiary requirements.

Examining the Collective Economic and Operational Implications of New United States Tariffs on In Silico Clinical Trial Innovations in 2025

Beginning in 2025, newly implemented United States tariffs targeting imported software components and specialized computing hardware have begun to influence the economic landscape of in silico clinical trials. While these measures aim to bolster domestic manufacturing and secure critical supply chains, they have introduced additional cost considerations for trial sponsors who rely on high-performance servers, graphical processing units, and third-party algorithmic libraries. As a direct result, some organizations have engaged in strategic negotiation with vendors to mitigate price fluctuations and ensure continuity of simulation workflows.

Moreover, the tariff framework has prompted a reevaluation of geographically distributed computing strategies, with many stakeholders exploring local cloud service providers and colocation facilities to circumvent cross-border duties. This recalibration has yielded a nuanced cost-efficiency trade-off: while domestic alternatives may limit exposure to import levies, they often necessitate investments in data sovereignty compliance and system integration. In this context, in silico trial teams must balance cost containment against performance considerations to maintain rigorous model fidelity.

Operationally, the ripple effects extend beyond hardware procurement. Software licensing fees linked to imported modules have risen, driving some entities to adopt open-source or domestically developed solutions. Transitioning to new platforms, however, can entail validation overhead and temporary disruption. Nonetheless, proactive planning and vendor partnerships have enabled many trial sponsors to preserve their simulation pipelines, safeguarding the strategic momentum of ongoing research initiatives. These collective adaptations highlight the resilience of the ecosystem in navigating policy-driven headwinds, while underscoring the importance of supply chain agility in sustaining in silico trial innovation.

Unveiling Core Segmentation Insights That Illuminate Market Dynamics Across Diverse Product Types, Phases, and Technological Platforms

An in depth exploration of market segmentation reveals pivotal insights into how different facets of the in silico clinical trial ecosystem interact and drive adoption. When examining segmentation by product type, it becomes clear that service offerings such as consulting and training, custom simulation services, and model development and validation play a complementary role alongside software solutions that encompass simulation platforms, trial design tools, and virtual patient modeling applications. Together, these categories enable end-to-end support for research teams seeking both expertise and technological foundations.

By focusing on trial phases, stakeholders observe that early-stage investigations in Phase I and Phase II benefit from lightweight simulation iterations that validate safety and pharmacokinetics, whereas more sophisticated mechanistic and population-based modeling assume greater prominence in Phase III and Phase IV trials to optimize efficacy assessments and post-market surveillance. Meanwhile, the underlying technology platforms-ranging from artificial intelligence and machine learning engines to cloud-based simulations, digital twin architectures, mechanistic modeling frameworks, and virtual patient populations-each contribute distinct capabilities, whether in predictive analytics, scalability, or physiological fidelity.

Application oriented segmentation further demonstrates that disease modeling, drug development, and medical device testing each exploit in silico approaches to meet specialized protocol objectives. Finally, therapeutic area segmentation underscores the breadth of focus, spanning cardiovascular simulations for arrhythmia or heart failure, infectious disease predictions, neurological disorder models, oncology simulations for solid tumors and hematologic malignancies, and the nuanced modeling required for rare genetic disorders. This holistic segmentation analysis illuminates how tailored solutions can address bespoke research questions across the full spectrum of clinical investigation.

Decoding Regional Variations and Strategic Nuances That Shape the In Silico Clinical Trial Landscape Across Global Geographies

Analyzing the geographic dimensions of in silico clinical trials reveals region-specific drivers and barriers that shape adoption and development trajectories. In the Americas, robust investment in life sciences infrastructure and a collaborative ecosystem that includes leading academic institutions and contract research organizations have accelerated the deployment of advanced simulation frameworks. North American regulatory clarity, particularly around model-informed drug development guidance, has further incentivized early adoption by both small innovators and established pharmaceutical companies.

Across Europe, the Middle East, and Africa, a mosaic of regulatory standards and market maturity levels presents both challenges and opportunities. Western European nations, buoyed by progressive regulatory councils, have championed public-private partnerships to validate digital twin initiatives, whereas emerging markets within EMEA are gradually building capacity through targeted government funding and regional research consortia. Navigating this heterogeneous landscape requires tailored engagement strategies that align with divergent compliance requirements and local clinical infrastructures.

In the Asia-Pacific region, rapid digital transformation and expanding biotech clusters in markets such as China, Japan, and South Korea have propelled wide-scale experimentation with mechanistic modeling and virtual patient populations. These markets benefit from substantial government incentives aimed at modernizing drug development pipelines and addressing regional health priorities. However, distinct data privacy regulations and divergent validation expectations necessitate careful alignment with local standards. Collectively, these regional insights underscore the importance of contextualized strategies that respect regulatory nuance, leverage local strengths, and forge strategic partnerships to maximize the impact of in silico clinical trials on a global scale.

Highlighting Leading Organizations and Their Strategic Initiatives Driving Innovation and Competitive Advantage in In Silico Trial Solutions

Within the competitive landscape of in silico clinical trials, leading organizations have charted distinct innovation pathways that underscore the sector's dynamism. Some pioneering firms have invested heavily in proprietary simulation platforms that integrate mechanistic and data-driven approaches, delivering turnkey solutions for virtual patient modeling and trial design. Others have established specialized service divisions that offer custom simulation programs and validation services, enabling sponsors to outsource complex modeling tasks while maintaining stringent quality controls.

Strategic partnerships between software developers and contract research organizations have emerged as a powerful avenue for scaling simulation capabilities across multiple therapeutic areas. By combining technological expertise with deep domain knowledge, these alliances facilitate seamless integration of computational workflows into existing trial protocols, reducing deployment time and enhancing reproducibility. This collaborative trend extends to academic partnerships, where institutions contribute validation data sets and real-world evidence, bolstering model credibility and expanding application scope.

Several market frontrunners have also embraced open innovation strategies, fostering ecosystems that encourage third-party developers to build specialized modules and plugins. This modular approach not only accelerates feature enhancements but also democratizes access to cutting-edge tools without sacrificing performance. Concurrently, an emphasis on user experience and intuitive interfaces has made advanced simulation capabilities more accessible to non-computational scientists, driving deeper cross-functional adoption. Collectively, these company-driven tactics highlight a convergence of technology, expertise, and collaboration that continues to elevate the quality and scope of in silico clinical trial solutions.

Recommending Strategic Actions for Industry Leaders to Accelerate Adoption and Optimize Outcomes in Simulated Clinical Testing Environments

To fully realize the value of in silico clinical trials, industry leaders must adopt a multi-pronged approach that balances strategic investment, cross-disciplinary collaboration, and regulatory engagement. First, establishing dedicated governance frameworks ensures that modeling standards, validation protocols, and data management practices align with both internal quality benchmarks and external regulatory expectations. By fostering transparent model development and documentation workflows, organizations can streamline regulatory submissions and build trust with oversight bodies.

Second, cultivating partnerships across the ecosystem-encompassing software developers, contract research organizations, academic centers, and technology vendors-enables access to complementary expertise while sharing the burden of infrastructure investment. Such alliances should prioritize open data standards and interoperability to maximize the reuse of models and accelerate validation cycles. In parallel, industry leaders should invest in upskilling programs that equip clinical scientists with computational fluency, ensuring that teams can interpret simulation outputs and integrate insights into trial design decisions.

Third, adopting a phased implementation roadmap allows for incremental refinement of in silico methodologies, starting with pilot projects in late-stage research and progressively scaling to encompass earlier discovery phases. This approach reduces disruption, enables early identification of capability gaps, and fosters continuous improvement based on real-world feedback. Finally, engaging proactively with regulatory agencies through pilot programs, workshops, and joint task forces facilitates the co-creation of model acceptance criteria and paves the way for broader adoption. By executing these recommendations, industry stakeholders can harness the full potential of simulated trials to drive efficiency, minimize risk, and deliver patient-centric innovations.

Detailing the Rigorous Research Methodology Underpinning the Depth, Reliability, and Reproducibility of In Silico Clinical Trials Market Analysis

Underpinning this analysis is a comprehensive research methodology designed to ensure depth, rigor, and reproducibility. The process began with the systematic review of peer-reviewed literature and regulatory guidance documents to establish foundational definitions and identify best practices in in silico modeling. These insights informed a series of structured expert interviews with clinical scientists, computational biologists, regulatory specialists, and technology providers, capturing firsthand perspectives on emerging trends, validation challenges, and adoption barriers.

Subsequently, secondary data sources were triangulated to map technology adoption patterns, service delivery models, and partnership dynamics across major markets. Market activities were validated through cross-referenced public disclosures, corporate whitepapers, and conference proceedings. This multi-source integration enabled the synthesis of segmentation frameworks, regional variations, and company initiatives with both qualitative nuance and quantitative granularity.

To ensure methodological validity, a series of internal peer reviews was conducted, scrutinizing assumptions, data provenance, and analytical frameworks. Model scenarios were stress-tested against historical case studies, confirming alignment between simulated outcomes and documented trial results. Finally, a peer validation panel comprising independent academic and industry experts evaluated the findings, providing critical feedback to refine the narrative and ensure balanced, actionable insights. Through this layered approach, the study delivers a robust, transparent analysis poised to inform strategic decision-making in the evolving domain of in silico clinical trials.

Synthesizing Key Takeaways and Future Outlook to Inform Stakeholders About the Strategic Trajectory of In Silico Clinical Trials

As computational modeling continues to mature, in silico clinical trials are poised to redefine the contours of drug development and regulatory approval. The integration of mechanistic frameworks, digital twin constructs, and advanced analytics has already demonstrated the capacity to optimize trial design, enhance safety profiling, and accelerate go-to-market timelines. Moreover, the growing alignment between simulation outcomes and empirical results underscores the method's credibility, catalyzing broader acceptance among sponsors, regulators, and clinical investigators.

The sector's trajectory suggests that hybrid trial designs-combining virtual cohorts with traditional arms-will become the norm, enabling resource-efficient studies that maintain rigorous scientific standards. Geopolitical developments, such as the introduction of tariffs, highlight the importance of supply chain resilience and strategic sourcing of computational infrastructure. Meanwhile, segmentation insights emphasize that tailored solutions must evolve to address distinct therapeutic areas, technology platforms, and end-user requirements.

Ultimately, stakeholders who invest in robust governance frameworks, cross-disciplinary partnerships, and continuous upskilling will secure a competitive advantage in this rapidly shifting landscape. By proactively engaging with regulatory agencies to define validation criteria and evidentiary standards, organizations can expedite adoption and minimize uncertainty. In summary, the convergence of technology innovation, regulatory openness, and collaborative ecosystems will drive the next wave of breakthroughs in clinical research, delivering safer, more effective therapies to patients worldwide.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Development of hybrid in silico and real-world evidence platforms to accelerate oncology drug approval processes
  • 5.2. Implementation of regulatory framework alignment for computational trial evidence submission in major global markets
  • 5.3. Integration of mechanistic digital twin simulations for pediatric rare disease drug development
  • 5.4. Adoption of advanced AI-driven pharmacokinetic and pharmacodynamic modeling for personalized virtual patient cohorts
  • 5.5. Leveraging cloud-based high-performance computing to scale virtual clinical trials across geographically diverse populations

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. In Silico Clinical Trials Market, by Product Type

  • 8.1. Introduction
  • 8.2. Services
    • 8.2.1. Consulting & Training
    • 8.2.2. Custom Simulation Services
    • 8.2.3. Model development & validation
  • 8.3. Software Solutions
    • 8.3.1. Simulation Software
    • 8.3.2. Trial Design Software
    • 8.3.3. Virtual Patient Modeling

9. In Silico Clinical Trials Market, by Phase

  • 9.1. Introduction
  • 9.2. Phase I
  • 9.3. Phase II
  • 9.4. Phase III
  • 9.5. Phase IV

10. In Silico Clinical Trials Market, by Technology Platform

  • 10.1. Introduction
  • 10.2. Artificial Intelligence & Machine Learning
  • 10.3. Cloud-Based Simulations
  • 10.4. Digital Twin
  • 10.5. Mechanistic Modeling
  • 10.6. Virtual Patient Population

11. In Silico Clinical Trials Market, by Application

  • 11.1. Introduction
  • 11.2. Disease Modeling
  • 11.3. Drug Development
  • 11.4. Medical Device Testing

12. In Silico Clinical Trials Market, by Therapeutic Area

  • 12.1. Introduction
  • 12.2. Cardiovascular
    • 12.2.1. Arrhythmia Simulation
    • 12.2.2. Atherosclerosis Simulation
    • 12.2.3. Heart Failure Modeling
  • 12.3. Infectious Diseases
    • 12.3.1. Parasitic Disease Prediction
    • 12.3.2. Viral Infection Simulation
  • 12.4. Neurology
    • 12.4.1. Alzheimer's Simulation
    • 12.4.2. Epilepsy Simulation
    • 12.4.3. Parkinson's Disease Modeling
  • 12.5. Oncology
    • 12.5.1. Hematologic Malignancies
    • 12.5.2. Solid Tumors
  • 12.6. Rare Diseases
    • 12.6.1. Genetic Disorder Simulation
    • 12.6.2. Orphan Drug Modeling

13. In Silico Clinical Trials Market, by End User

  • 13.1. Introduction
  • 13.2. Academic & Research Institutes
  • 13.3. Contract Research Organizations
  • 13.4. Medical Device Companies
  • 13.5. Pharmaceutical & Biotech Companies
  • 13.6. Regulatory Agencies

14. Americas In Silico Clinical Trials Market

  • 14.1. Introduction
  • 14.2. United States
  • 14.3. Canada
  • 14.4. Mexico
  • 14.5. Brazil
  • 14.6. Argentina

15. Europe, Middle East & Africa In Silico Clinical Trials Market

  • 15.1. Introduction
  • 15.2. United Kingdom
  • 15.3. Germany
  • 15.4. France
  • 15.5. Russia
  • 15.6. Italy
  • 15.7. Spain
  • 15.8. United Arab Emirates
  • 15.9. Saudi Arabia
  • 15.10. South Africa
  • 15.11. Denmark
  • 15.12. Netherlands
  • 15.13. Qatar
  • 15.14. Finland
  • 15.15. Sweden
  • 15.16. Nigeria
  • 15.17. Egypt
  • 15.18. Turkey
  • 15.19. Israel
  • 15.20. Norway
  • 15.21. Poland
  • 15.22. Switzerland

16. Asia-Pacific In Silico Clinical Trials Market

  • 16.1. Introduction
  • 16.2. China
  • 16.3. India
  • 16.4. Japan
  • 16.5. Australia
  • 16.6. South Korea
  • 16.7. Indonesia
  • 16.8. Thailand
  • 16.9. Philippines
  • 16.10. Malaysia
  • 16.11. Singapore
  • 16.12. Vietnam
  • 16.13. Taiwan

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Abzena Ltd.
    • 17.3.2. Aitia NV
    • 17.3.3. Certara, Inc.
    • 17.3.4. Dassault Systemes SE
    • 17.3.5. Evotec SE
    • 17.3.6. Exscientia Limited
    • 17.3.7. GNS Healthcare Inc.
    • 17.3.8. IBM Corporation
    • 17.3.9. ICON plc
    • 17.3.10. Immunetrics Inc.
    • 17.3.11. Insilico Medicine, Inc.
    • 17.3.12. InSilicoTrials Technologies SpA
    • 17.3.13. IQVIA Holdings Inc.
    • 17.3.14. Novadiscovery SA
    • 17.3.15. PAREXEL INTERNATIONAL, INC.
    • 17.3.16. Recursion Pharmaceuticals, Inc.
    • 17.3.17. Schrodinger, Inc.
    • 17.3.18. Simulations Plus, Inc.
    • 17.3.19. The AnyLogic Company
    • 17.3.20. Virtonomy GmbH
    • 17.3.21. WuXi AppTec Co., Ltd.
    • 17.3.22. ZMT Zurich MedTech AG

18. ResearchAI

19. ResearchStatistics

20. ResearchContacts

21. ResearchArticles

22. Appendix

LIST OF FIGURES

  • FIGURE 1. IN SILICO CLINICAL TRIALS MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 16. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS IN SILICO CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 18. AMERICAS IN SILICO CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES IN SILICO CLINICAL TRIALS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 20. UNITED STATES IN SILICO CLINICAL TRIALS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA IN SILICO CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA IN SILICO CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. ASIA-PACIFIC IN SILICO CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 24. ASIA-PACIFIC IN SILICO CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 25. IN SILICO CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. IN SILICO CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 27. IN SILICO CLINICAL TRIALS MARKET: RESEARCHAI
  • FIGURE 28. IN SILICO CLINICAL TRIALS MARKET: RESEARCHSTATISTICS
  • FIGURE 29. IN SILICO CLINICAL TRIALS MARKET: RESEARCHCONTACTS
  • FIGURE 30. IN SILICO CLINICAL TRIALS MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. IN SILICO CLINICAL TRIALS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY SERVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY CONSULTING & TRAINING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY CONSULTING & TRAINING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY CUSTOM SIMULATION SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY CUSTOM SIMULATION SERVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY MODEL DEVELOPMENT & VALIDATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY MODEL DEVELOPMENT & VALIDATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY SOFTWARE SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY SOFTWARE SOLUTIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY SIMULATION SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY SIMULATION SOFTWARE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY TRIAL DESIGN SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY TRIAL DESIGN SOFTWARE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY VIRTUAL PATIENT MODELING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY VIRTUAL PATIENT MODELING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY SOFTWARE SOLUTIONS, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY SOFTWARE SOLUTIONS, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY ARTIFICIAL INTELLIGENCE & MACHINE LEARNING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY ARTIFICIAL INTELLIGENCE & MACHINE LEARNING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY CLOUD-BASED SIMULATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY CLOUD-BASED SIMULATIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY DIGITAL TWIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY DIGITAL TWIN, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY MECHANISTIC MODELING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY MECHANISTIC MODELING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY VIRTUAL PATIENT POPULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY VIRTUAL PATIENT POPULATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY DISEASE MODELING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY DISEASE MODELING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY MEDICAL DEVICE TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY MEDICAL DEVICE TESTING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY ARRHYTHMIA SIMULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY ARRHYTHMIA SIMULATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY ATHEROSCLEROSIS SIMULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY ATHEROSCLEROSIS SIMULATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY HEART FAILURE MODELING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY HEART FAILURE MODELING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY CARDIOVASCULAR, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY PARASITIC DISEASE PREDICTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY PARASITIC DISEASE PREDICTION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY VIRAL INFECTION SIMULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY VIRAL INFECTION SIMULATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY ALZHEIMER'S SIMULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY ALZHEIMER'S SIMULATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY EPILEPSY SIMULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY EPILEPSY SIMULATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 87. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY PARKINSON'S DISEASE MODELING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY PARKINSON'S DISEASE MODELING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 89. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
  • TABLE 91. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 93. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 95. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 97. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 99. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY RARE DISEASES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 101. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY GENETIC DISORDER SIMULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY GENETIC DISORDER SIMULATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 103. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY ORPHAN DRUG MODELING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY ORPHAN DRUG MODELING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 105. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY RARE DISEASES, 2025-2030 (USD MILLION)
  • TABLE 107. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 109. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 111. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 113. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY MEDICAL DEVICE COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY MEDICAL DEVICE COMPANIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 115. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 117. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY REGULATORY AGENCIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL IN SILICO CLINICAL TRIALS MARKET SIZE, BY REGULATORY AGENCIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 119. AMERICAS IN SILICO CLINICAL TRIALS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 120. AMERICAS IN SILICO CLINICAL TRIALS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 121. AMERICAS IN SILICO CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 122. AMERICAS IN SILICO CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2025-2030 (USD MILLION)
  • TABLE 123. AMERICAS IN SILICO CLINICAL TRIALS MARKET SIZE, BY SOFTWARE SOLUTIONS, 2018-2024 (USD MILLION)
  • TABLE 124. AMERICAS IN SILICO CLINICAL TRIALS MARKET SIZE, BY SOFTWARE SOLUTIONS, 2025-2030 (USD MILLION)
  • TABLE 125. AMERICAS IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2024 (USD MILLION)
  • TABLE 126. AMERICAS IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2025-2030 (USD MILLION)
  • TABLE 127. AMERICAS IN SILICO CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 128. AMERICAS IN SILICO CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2030 (USD MILLION)
  • TABLE 129. AMERICAS IN SILICO CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 130. AMERICAS IN SILICO CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 131. AMERICAS IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 132. AMERICAS IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 133. AMERICAS IN SILICO CLINICAL TRIALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
  • TABLE 134. AMERICAS IN SILICO CLINICAL TRIALS MARKET SIZE, BY CARDIOVASCULAR, 2025-2030 (USD MILLION)
  • TABLE 135. AMERICAS IN SILICO CLINICAL TRIALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 136. AMERICAS IN SILICO CLINICAL TRIALS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 137. AMERICAS IN SILICO CLINICAL TRIALS MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS IN SILICO CLINICAL TRIALS MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
  • TABLE 139. AMERICAS IN SILICO CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 140. AMERICAS IN SILICO CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 141. AMERICAS IN SILICO CLINICAL TRIALS MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 142. AMERICAS IN SILICO CLINICAL TRIALS MARKET SIZE, BY RARE DISEASES, 2025-2030 (USD MILLION)
  • TABLE 143. AMERICAS IN SILICO CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS IN SILICO CLINICAL TRIALS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 145. AMERICAS IN SILICO CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS IN SILICO CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 147. UNITED STATES IN SILICO CLINICAL TRIALS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 148. UNITED STATES IN SILICO CLINICAL TRIALS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 149. UNITED STATES IN SILICO CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 150. UNITED STATES IN SILICO CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2025-2030 (USD MILLION)
  • TABLE 151. UNITED STATES IN SILICO CLINICAL TRIALS MARKET SIZE, BY SOFTWARE SOLUTIONS, 2018-2024 (USD MILLION)
  • TABLE 152. UNITED STATES IN SILICO CLINICAL TRIALS MARKET SIZE, BY SOFTWARE SOLUTIONS, 2025-2030 (USD MILLION)
  • TABLE 153. UNITED STATES IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2024 (USD MILLION)
  • TABLE 154. UNITED STATES IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2025-2030 (USD MILLION)
  • TABLE 155. UNITED STATES IN SILICO CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 156. UNITED STATES IN SILICO CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2030 (USD MILLION)
  • TABLE 157. UNITED STATES IN SILICO CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 158. UNITED STATES IN SILICO CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 159. UNITED STATES IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 160. UNITED STATES IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 161. UNITED STATES IN SILICO CLINICAL TRIALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
  • TABLE 162. UNITED STATES IN SILICO CLINICAL TRIALS MARKET SIZE, BY CARDIOVASCULAR, 2025-2030 (USD MILLION)
  • TABLE 163. UNITED STATES IN SILICO CLINICAL TRIALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 164. UNITED STATES IN SILICO CLINICAL TRIALS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 165. UNITED STATES IN SILICO CLINICAL TRIALS MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 166. UNITED STATES IN SILICO CLINICAL TRIALS MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
  • TABLE 167. UNITED STATES IN SILICO CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 168. UNITED STATES IN SILICO CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 169. UNITED STATES IN SILICO CLINICAL TRIALS MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 170. UNITED STATES IN SILICO CLINICAL TRIALS MARKET SIZE, BY RARE DISEASES, 2025-2030 (USD MILLION)
  • TABLE 171. UNITED STATES IN SILICO CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 172. UNITED STATES IN SILICO CLINICAL TRIALS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 173. UNITED STATES IN SILICO CLINICAL TRIALS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 174. UNITED STATES IN SILICO CLINICAL TRIALS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 175. CANADA IN SILICO CLINICAL TRIALS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. CANADA IN SILICO CLINICAL TRIALS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 177. CANADA IN SILICO CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 178. CANADA IN SILICO CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2025-2030 (USD MILLION)
  • TABLE 179. CANADA IN SILICO CLINICAL TRIALS MARKET SIZE, BY SOFTWARE SOLUTIONS, 2018-2024 (USD MILLION)
  • TABLE 180. CANADA IN SILICO CLINICAL TRIALS MARKET SIZE, BY SOFTWARE SOLUTIONS, 2025-2030 (USD MILLION)
  • TABLE 181. CANADA IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2024 (USD MILLION)
  • TABLE 182. CANADA IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2025-2030 (USD MILLION)
  • TABLE 183. CANADA IN SILICO CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 184. CANADA IN SILICO CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2030 (USD MILLION)
  • TABLE 185. CANADA IN SILICO CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 186. CANADA IN SILICO CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 187. CANADA IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 188. CANADA IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 189. CANADA IN SILICO CLINICAL TRIALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
  • TABLE 190. CANADA IN SILICO CLINICAL TRIALS MARKET SIZE, BY CARDIOVASCULAR, 2025-2030 (USD MILLION)
  • TABLE 191. CANADA IN SILICO CLINICAL TRIALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 192. CANADA IN SILICO CLINICAL TRIALS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 193. CANADA IN SILICO CLINICAL TRIALS MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 194. CANADA IN SILICO CLINICAL TRIALS MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
  • TABLE 195. CANADA IN SILICO CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 196. CANADA IN SILICO CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 197. CANADA IN SILICO CLINICAL TRIALS MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 198. CANADA IN SILICO CLINICAL TRIALS MARKET SIZE, BY RARE DISEASES, 2025-2030 (USD MILLION)
  • TABLE 199. CANADA IN SILICO CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 200. CANADA IN SILICO CLINICAL TRIALS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 201. MEXICO IN SILICO CLINICAL TRIALS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 202. MEXICO IN SILICO CLINICAL TRIALS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 203. MEXICO IN SILICO CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 204. MEXICO IN SILICO CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2025-2030 (USD MILLION)
  • TABLE 205. MEXICO IN SILICO CLINICAL TRIALS MARKET SIZE, BY SOFTWARE SOLUTIONS, 2018-2024 (USD MILLION)
  • TABLE 206. MEXICO IN SILICO CLINICAL TRIALS MARKET SIZE, BY SOFTWARE SOLUTIONS, 2025-2030 (USD MILLION)
  • TABLE 207. MEXICO IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2024 (USD MILLION)
  • TABLE 208. MEXICO IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2025-2030 (USD MILLION)
  • TABLE 209. MEXICO IN SILICO CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 210. MEXICO IN SILICO CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2030 (USD MILLION)
  • TABLE 211. MEXICO IN SILICO CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 212. MEXICO IN SILICO CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 213. MEXICO IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 214. MEXICO IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 215. MEXICO IN SILICO CLINICAL TRIALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
  • TABLE 216. MEXICO IN SILICO CLINICAL TRIALS MARKET SIZE, BY CARDIOVASCULAR, 2025-2030 (USD MILLION)
  • TABLE 217. MEXICO IN SILICO CLINICAL TRIALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 218. MEXICO IN SILICO CLINICAL TRIALS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 219. MEXICO IN SILICO CLINICAL TRIALS MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 220. MEXICO IN SILICO CLINICAL TRIALS MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
  • TABLE 221. MEXICO IN SILICO CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 222. MEXICO IN SILICO CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 223. MEXICO IN SILICO CLINICAL TRIALS MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 224. MEXICO IN SILICO CLINICAL TRIALS MARKET SIZE, BY RARE DISEASES, 2025-2030 (USD MILLION)
  • TABLE 225. MEXICO IN SILICO CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 226. MEXICO IN SILICO CLINICAL TRIALS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 227. BRAZIL IN SILICO CLINICAL TRIALS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. BRAZIL IN SILICO CLINICAL TRIALS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 229. BRAZIL IN SILICO CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 230. BRAZIL IN SILICO CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2025-2030 (USD MILLION)
  • TABLE 231. BRAZIL IN SILICO CLINICAL TRIALS MARKET SIZE, BY SOFTWARE SOLUTIONS, 2018-2024 (USD MILLION)
  • TABLE 232. BRAZIL IN SILICO CLINICAL TRIALS MARKET SIZE, BY SOFTWARE SOLUTIONS, 2025-2030 (USD MILLION)
  • TABLE 233. BRAZIL IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2024 (USD MILLION)
  • TABLE 234. BRAZIL IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2025-2030 (USD MILLION)
  • TABLE 235. BRAZIL IN SILICO CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 236. BRAZIL IN SILICO CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2030 (USD MILLION)
  • TABLE 237. BRAZIL IN SILICO CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 238. BRAZIL IN SILICO CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 239. BRAZIL IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 240. BRAZIL IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 241. BRAZIL IN SILICO CLINICAL TRIALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
  • TABLE 242. BRAZIL IN SILICO CLINICAL TRIALS MARKET SIZE, BY CARDIOVASCULAR, 2025-2030 (USD MILLION)
  • TABLE 243. BRAZIL IN SILICO CLINICAL TRIALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 244. BRAZIL IN SILICO CLINICAL TRIALS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 245. BRAZIL IN SILICO CLINICAL TRIALS MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 246. BRAZIL IN SILICO CLINICAL TRIALS MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
  • TABLE 247. BRAZIL IN SILICO CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 248. BRAZIL IN SILICO CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 249. BRAZIL IN SILICO CLINICAL TRIALS MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 250. BRAZIL IN SILICO CLINICAL TRIALS MARKET SIZE, BY RARE DISEASES, 2025-2030 (USD MILLION)
  • TABLE 251. BRAZIL IN SILICO CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 252. BRAZIL IN SILICO CLINICAL TRIALS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 253. ARGENTINA IN SILICO CLINICAL TRIALS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. ARGENTINA IN SILICO CLINICAL TRIALS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 255. ARGENTINA IN SILICO CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 256. ARGENTINA IN SILICO CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2025-2030 (USD MILLION)
  • TABLE 257. ARGENTINA IN SILICO CLINICAL TRIALS MARKET SIZE, BY SOFTWARE SOLUTIONS, 2018-2024 (USD MILLION)
  • TABLE 258. ARGENTINA IN SILICO CLINICAL TRIALS MARKET SIZE, BY SOFTWARE SOLUTIONS, 2025-2030 (USD MILLION)
  • TABLE 259. ARGENTINA IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2024 (USD MILLION)
  • TABLE 260. ARGENTINA IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2025-2030 (USD MILLION)
  • TABLE 261. ARGENTINA IN SILICO CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 262. ARGENTINA IN SILICO CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2030 (USD MILLION)
  • TABLE 263. ARGENTINA IN SILICO CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 264. ARGENTINA IN SILICO CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 265. ARGENTINA IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 266. ARGENTINA IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 267. ARGENTINA IN SILICO CLINICAL TRIALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
  • TABLE 268. ARGENTINA IN SILICO CLINICAL TRIALS MARKET SIZE, BY CARDIOVASCULAR, 2025-2030 (USD MILLION)
  • TABLE 269. ARGENTINA IN SILICO CLINICAL TRIALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 270. ARGENTINA IN SILICO CLINICAL TRIALS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 271. ARGENTINA IN SILICO CLINICAL TRIALS MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 272. ARGENTINA IN SILICO CLINICAL TRIALS MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
  • TABLE 273. ARGENTINA IN SILICO CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 274. ARGENTINA IN SILICO CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 275. ARGENTINA IN SILICO CLINICAL TRIALS MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 276. ARGENTINA IN SILICO CLINICAL TRIALS MARKET SIZE, BY RARE DISEASES, 2025-2030 (USD MILLION)
  • TABLE 277. ARGENTINA IN SILICO CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 278. ARGENTINA IN SILICO CLINICAL TRIALS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA IN SILICO CLINICAL TRIALS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA IN SILICO CLINICAL TRIALS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA IN SILICO CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA IN SILICO CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2025-2030 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA IN SILICO CLINICAL TRIALS MARKET SIZE, BY SOFTWARE SOLUTIONS, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA IN SILICO CLINICAL TRIALS MARKET SIZE, BY SOFTWARE SOLUTIONS, 2025-2030 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA IN SILICO CLINICAL TRIALS MARKET SIZE, BY PHASE, 2025-2030 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA IN SILICO CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA IN SILICO CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2030 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA IN SILICO CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA IN SILICO CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA IN SILICO CLINICAL TRIALS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA IN SILICO CLINICAL TRIALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA IN SILICO CLINICAL TRIALS MARKET SIZE, BY CARDIOVASCULAR, 2025-2030 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA IN SILICO CLINICAL TRIALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA IN SILICO CLINICAL TRIALS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA IN SILICO CLINICAL TRIALS MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE, MIDDLE EAST & AFRICA IN SILICO CLINICAL TRIALS MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
  • TABLE 299. EUROPE, MIDDLE EAST & AFRICA IN SILICO CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE, MIDDLE EAST & AFRICA IN SILICO CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 301. EUROPE, MIDDLE EAST & AFRICA IN SILICO CLINICAL TRIALS MARKET SIZE, BY RARE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE, MIDDLE EAST & AFRICA IN SILICO CLINICAL TRIALS MARKET SIZE, BY RARE DISEASES, 2025-2030 (USD MILLION)
  • TABLE 303. EUROPE, MIDDLE EAST & AFRICA IN SILICO CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE, MIDDLE EAST & AFRICA IN SILICO CLINICAL TRIALS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 305. EUROPE, MIDDLE EAST & AFRICA IN SILICO CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE, MIDDLE EAST & AFRICA IN SILICO CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 307. UNITED KINGDOM IN SILICO CLINICAL TRIALS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 308. UNITED KINGDOM IN SILICO CLINICAL TRIALS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 309. UNITED KINGDOM IN SILICO CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 310. UNITED KINGDOM IN SILICO CLINICAL TRIALS MARKET SIZE, BY SERVICES, 2025-2030 (USD MILLION)